Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 7/20 | 0.39 |
| ▸ | HTR3A | P46098 | 7/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11822275 | 0.82 | TP53 (0.44) | TP53TDP1HAO1HPGDPKM | |
| SCHEMBL2019539 | 0.80 | HSD17B10 (0.43) | TP53TDP1HPGDSMN1; SMN2LMNA | |
| SCHEMBL76793 | 0.79 | HAO1 (0.55) | TP53TDP1HAO1HPGDPKM | |
| SCHEMBL29411684 | 0.79 | NPC1 (0.50) | TP53TDP1HAO1HPGDPKM | |
| SCHEMBL29475022 | 0.79 | HAO1 (0.55) | TP53TDP1HAO1HPGDPKM | |
| SCHEMBL576257 | 0.79 | NPC1 (0.50) | TP53TDP1HAO1HPGDPKM | |
| SCHEMBL23912809 | 0.78 | CYP1A2 (0.40) | TP53TDP1HPGDSMN1; SMN2HTR1A | |
| SCHEMBL735441 | 0.77 | HSD17B10 (0.44) | TP53TDP1HAO1HPGDPKM | |
| SCHEMBL23912730 | 0.76 | NFE2L2 (0.36) | TP53TDP1HPGDSMN1; SMN2HTR1A | |
| SCHEMBL25613587 | 0.76 | ACHE (0.35) | SMN1; SMN2CYP1A2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015079018-A1 | SYNTHESIS OF VORTIOXETINE VIA (2-(PIPERAZINE-1 -YL)PHENVL)LITHIUM INTERMEDIATES | LEK PHARMACEUTICALS D.D. (SI) | 2015-06-04 | — | — | WO | claimed |
| EP-2878596-A1 | Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates | LEK Pharmaceuticals d.d. (SI) | 2015-06-03 | — | — | EP | claimed |
| EP-1939204-B3 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2022-08-24 | — | — | EP | disclosed |
| CN-105939995-A | Synthesis of vortioxetine via (2-(piperazine-1 -yl)phenvl)lithium intermediates | 斯洛文尼亚莱柯制药股份有限公司 | 2016-09-14 | — | — | CN | disclosed |
| WO-2015079018-A1 | SYNTHESIS OF VORTIOXETINE VIA (2-(PIPERAZINE-1 -YL)PHENVL)LITHIUM INTERMEDIATES | LEK PHARMACEUTICALS D.D. (SI) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015079018-A1 | SYNTHESIS OF VORTIOXETINE VIA (2-(PIPERAZINE-1 -YL)PHENVL)LITHIUM INTERMEDIATES | LEK PHARMACEUTICALS D.D. (SI) | 2015-06-04 | — | — | WO | disclosed |
| EP-2878596-A1 | Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates | LEK Pharmaceuticals d.d. (SI) | 2015-06-03 | — | — | EP | disclosed |
| EP-2878596-A1 | Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates | LEK Pharmaceuticals d.d. (SI) | 2015-06-03 | — | — | EP | disclosed |
| US-20110160488-A1 | Fluorination Processes with Arylsulfur Halotetrafluorides | I M &T RESEARCH, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2009114409-A2 | FLUORINATION PROCESSES WITH ARYLSULFUR HALOTETRAFLUORIDES | IM & T RESEARCH, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160488-A1 | Fluorination Processes with Arylsulfur Halotetrafluorides | CYP2F1, PFAS, CYP4F2 | TP53 3229/4885TDP1 2506/4885HAO1 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.